Elicio Therapeutics is a privately-held clinical-stage biotechnology company. It involved in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. Elicio Therapeutics, formerly known as Angion Biomedica Corp, is based in BOSTON.
| Revenue (Most Recent Fiscal Year) | $2.30M |
| Net Income (Most Recent Fiscal Year) | $-51.90M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 91.85 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -175.83% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.28 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.28 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 5.09 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.11 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.66 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.25 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.94 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 16.34M |
| Free Float | 11.66M |
| Market Capitalization | $172.04M |
| Average Volume (Last 20 Days) | 0.15M |
| Beta (Past 60 Months) | 1.19 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 28.65% |
| Percentage Held By Institutions (Latest 13F Reports) | 35.03% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |